Testosterone depot injection in male hypogonadism: a critical appraisal

References

• AndersonRA1996Comparison between testosterone enanthate-induced azoospermia and oligozoospermia in a male contraceptive study. III. Higher 5 alpha-reductase activity in oligozoospermic men administered supraphysiological doses of testosteroneJ Clin Endocrinol Metab8190288772548
   PubMed Web of Science ®Google Scholar
• BagatellCJBremnerWJ1995Androgen and progestagen effects on plasma lipidsProg Cardiovasc Dis38255717494886
   PubMed Web of Science ®Google Scholar
• BagchusWM2003Important effect of food on the bioavailability of oral testosterone undecanoatePharmacotherapy233192512627930
   PubMed Web of Science ®Google Scholar
• BehreHM1994Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controlsClin Endocrinol (Oxf)4034197514512
   PubMed Web of Science ®Google Scholar
• BehreHM2004Pharmacology of testosterone preparationsNieschlagEBehreHMTestosterone, action, deficiency, substitutionCambridge University Press40544
   Google Scholar
• BhasinS2003Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring planJ Androl2429931112721204
   PubMed Web of Science ®Google Scholar
• BhasinS2006Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guidelineJ Clin Endocrinol Metab911995201016720669
   PubMed Web of Science ®Google Scholar
• BoorjianSA2005Does the time from biopsy to surgery affect biochemical recurrence after radical prostatectomy?BJU Int96773616153197
   PubMed Web of Science ®Google Scholar
• BrachetC2005Children’s virilization and the use of a testosterone gel by their fathersEur J Pediatr164646716025298
   PubMed Web of Science ®Google Scholar
• CalliesF2003Testosterone undecanoate: a useful tool for testosterone administration in ratsExp Clin Endocrinol Diabetes111203812845558
   PubMed Web of Science ®Google Scholar
• CarrubaG2006Estrogens and mechanisms of prostate cancer progressionAnn N Y Acad Sci10892011717261768
   PubMed Web of Science ®Google Scholar
• CrabbeP1980Injectable contraceptive synthesis: an example of international cooperationScience20999247403868
   PubMed Web of Science ®Google Scholar
• DobsAS1999Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal menJ Clin Endocrinol Metab8434697810522982
   PubMed Web of Science ®Google Scholar
• DobsAS2004Short-term pharmacokinetic comparison of a novel testosterone buccal system and a testosterone gel in testosterone deficient menCurr Med Res Opin207293815140340
   PubMed Web of Science ®Google Scholar
• GoorenLJBunckMC2004Androgen replacement therapy: present and futureDrugs6418619115329035
   PubMed Web of Science ®Google Scholar
• GoorenLJSaadF2006Recent insights into androgen action on the anatomical and physiological substrate of penile erectionAsian J Androl83916372114
   PubMed Web of Science ®Google Scholar
• GraefenM2005Reasonable delay of surgical treatment in men with localized prostate cancer – impact on prognosis?Eur Urol477566015925069
   PubMed Web of Science ®Google Scholar
• GuYQ2003A multicenter contraceptive efficacy study of injectable testosterone undecanoate in healthy Chinese menJ Clin Endocrinol Metab88562812574181
   PubMed Web of Science ®Google Scholar
• GuiYL2004Male hormonal contraception: suppression of spermatogenesis by injectable testosterone undecanoate alone or with levonorgestrel implants in chinese menJ Androl25720715292101
   PubMed Web of Science ®Google Scholar
• HarleL2005Nebido: a long-acting injectable testosterone for the treatment of male hypogonadismExpert Opin Pharmacother61751916086661
   PubMed Web of Science ®Google Scholar
• HerzJE1985Potential long-acting contraceptive agents: esters and ethers of testosterone with alpha- and/or beta-chain branchingSteroids46947533842023
   PubMed Web of Science ®Google Scholar
• HorstHJ1976Lymphatic absorption and metabolism of orally administered testosterone undecanoate in manKlin Wochenschr548759966635
   PubMedGoogle Scholar
• JacobeitJWSchulteHM2006Long-acting intramuscular testosterone undecanoate (TU, Nebido®) in treatment of aging males with hypogonadism8th European Congress of EndocrinologyGlasgow1–542006 Poster No. P184
   Google Scholar
• JockenhovelF1997Effects of various modes of androgen substitution therapy on erythropoiesisEur J Med Res229389233903
   PubMedGoogle Scholar
• KelleherS2004Testosterone release rate and duration of action of testosterone pellet implantsClin Endocrinol (Oxf)60420815049955
   PubMed Web of Science ®Google Scholar
• LyLP2001A double-blind, placebo-controlled, randomized clinical trial of transdermal dihydrotestosterone gel on muscular strength, mobility, and quality of life in older men with partial androgen deficiencyJ Clin Endocrinol Metab8640788811549629
   PubMed Web of Science ®Google Scholar
• MeikleAW1996Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: influence of application site – a clinical research center studyJ Clin Endocrinol Metab811832408626843
   PubMed Web of Science ®Google Scholar
• MeikleAW2004Transdermal testosterone gel: pharmacokinetics, efficacy of dosing and application site in hypogonadal menBJU Int937899515049991
   PubMed Web of Science ®Google Scholar
• MinnemannT2007A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoateAging Male10155817701659
   PubMed Web of Science ®Google Scholar
• MoralesA2006Clinical experience with the new long-acting injectable testosterone undecanoate. Report on the educational symposium on the occasion of the 5th World Congress on the Aging Male, 9–12 February 2006, Salzburg, AustriaAging Male9221717178558
   PubMed Web of Science ®Google Scholar
• MorgentalerARhodenEL2006Prevalence of prostate cancer among hypogonadal men with prostate-specific antigen levels of 4.0 ng/mL or lessUrology681263717169647
   PubMed Web of Science ®Google Scholar
• NieschlagE2006Testosterone treatment comes of age: new options for hypogonadal menClin Endocrinol (Oxf)652758116918944
   PubMed Web of Science ®Google Scholar
• NieschlagE1999Repeated intramuscular injections of testosterone undecanoate for substitution therapy in hypogonadal menClin Endocrinol (Oxf)517576310619981
   PubMed Web of Science ®Google Scholar
• NieschlagE2005Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, and EAU recommendationsInt J Androl28125715910536
   PubMed Web of Science ®Google Scholar
• O’ConnorDB2004Effects of testosterone on mood, aggression, and sexual behavior in young men: a double-blind, placebo-controlled, cross-over studyJ Clin Endocrinol Metab8928374515181066
   PubMed Web of Science ®Google Scholar
• PartschCJ1995Injectable testosterone undecanoate has more favourable pharmacokinetics and pharmacodynamics than testosterone enanthateEur J Endocrinol13251497711892
   PubMed Web of Science ®Google Scholar
• RolfC2002Interpersonal testosterone transfer after topical application of a newly developed testosterone gel preparationClin Endocrinol (Oxf)566374112030915
   PubMed Web of Science ®Google Scholar
• SchubertM2004Intramuscular testosterone undecanoate: pharmacokinetic aspects of a novel testosterone formulation during long-term treatment of men with hypogonadismJ Clin Endocrinol Metab8954293415531493
   PubMed Web of Science ®Google Scholar
• StuenkelCA1991Sublingual administration of testosterone-hydroxypropyl-beta-cyclodextrin inclusion complex simulates episodic androgen release in hypogonadal menJ Clin Endocrinol Metab72105491902483
   PubMed Web of Science ®Google Scholar
• TraishAM2005Adipocyte accumulation in penile corpus cavernosum of the orchiectomized rabbit: a potential mechanism for veno-occlusive dysfunction in androgen deficiencyJ Androl26242815713830
   PubMed Web of Science ®Google Scholar
• TraishAMGuayAT2006Are androgens critical for penile erections in humans? Examining the clinical and preclinical evidenceJ Sex Med3382404 discussion 404–716681465
   PubMed Web of Science ®Google Scholar
• von EckardsteinSNieschlagE2002Treatment of male hypogonadism with testosterone undecanoate injected at extended intervals of 12-weeks: a phase II studyJ Androl234192512002444
   PubMedGoogle Scholar
• WangCSwerdloffRS2002Should the nonaromatizable androgen dihydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause?J Clin Endocrinol Metab871462611932265
   PubMed Web of Science ®Google Scholar
• WangC2000Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal menJ Clin Endocrinol Metab8528395310946892
   PubMed Web of Science ®Google Scholar
• WangC1996Sublingual testosterone replacement improves muscle mass and strength, decreases bone resorption, and increases bone formation markers in hypogonadal men – a clinical research center studyJ Clin Endocrinol Metab813654628855818
   PubMed Web of Science ®Google Scholar
• WangC2004aLong-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal menJ Clin Endocrinol Metab8920859815126525
   PubMed Web of Science ®Google Scholar
• WangC2004bNew testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal menJ Clin Endocrinol Metab893821915292312
   PubMed Web of Science ®Google Scholar
• YassinA2007Comparison of the efficacy drawbacks of two modalities of testosterone treatment: transdermal testosterone gel and injectable long-acting testosterone undecanoateJ Sex Med4Suppl 184
   Google Scholar
• YassinASaadF2005Does long-acting testosterone injection (Nebido) have an impact on DHTInt J Androl2863
   Google Scholar
• YassinAASaadF2006aDramatic improvement of penile venous leakage upon testosterone administration. A case report and review of literatureAndrologia3834716420241
   PubMed Web of Science ®Google Scholar
• YassinAASaadF2006bTreatment of sexual dysfunction of hypogonadal patients with long-acting testosterone undecanoate (Nebido®)World J Urol246394417048032
   PubMed Web of Science ®Google Scholar
• YassinASaadF2007Improvement of sexual functions in men with late onset hypogonadism treated with testosterone onlyJ Sex Med449750117367445
   PubMed Web of Science ®Google Scholar
• YassinAA2006Testosterone undecanoate restores erectile function in a subset of patients with venous leakage: a series of case reportsJ Sex Med37273516839330
   PubMed Web of Science ®Google Scholar
• ZhangGY1998A pharmacokinetic study of injectable testosterone undecanoate in hypogonadal menJ Androl1976189876028
   PubMed Web of Science ®Google Scholar
• ZhangL2006The acceptability of an injectable, once-a-month male contraceptive in ChinaContraception735485316627044
   PubMed Web of Science ®Google Scholar
• ZitzmannMN2006long-term experience of more than 8 years with a novel formulation of testosterone undecanoate (Nebido) in substitution therapy of hypogonadal menAging Male55
   Google Scholar
• ZitzmannM2005Long-term experience with injections of testosterone undecanoate for substitution therapy in hypogonadal men87th Annual Meeting of the Endocrine Society200564–7San Diego, CA306
   Google Scholar
• ZitzmannM2007New models to improve safety of testosterone substitution by pharmacogenetics and obesity status: experience of 118 treatment-years with a long-acting formulation of testosterone undecanoate Endocrine Society, Abstract book4401
   Google Scholar